My bookmarksSign up free
Source

Commission Regulation (EU) 2018/1480 of 4 October 2018 amending, for the purposes of its adaptation to technical and scientific progress, Regulation (EC) No 1272/2008 of the European Parliament and of the Council on classification, labelling and packaging of substances and mixtures and correcting Commission Regulation (EU) 2017/776 (Text with EEA relevance.)

Commission Regulation (EU) 2018/1480 of 4 October 2018 amending, for the purposes of its adaptation to technical and scientific progress, Regulation (EC) No 1272/2008 of the European Parliament and of the Council on classification, labelling and packaging of substances and mixtures and correcting Commission Regulation (EU) 2017/776 (Text with EEA relevance.)

Regulation (EU) 2018/1480 · Regulation · 4 articles

Data as of 2026-07-04 · Compiled from an official source version. Later amendments or repeals may not be reflected; the official text prevails. · Read the official text ↗

Amendment to Regulation (EC) No 1272/2008

Article 1

Open ↗

Annex VI to Regulation (EC) No 1272/2008 is amended as set out in the Annex to this Regulation.

Correction to Regulation (EU) 2017/776

Article 2

Open ↗

In Regulation (EU) 2017/776, the second subparagraph of Article 2(2) is replaced by the following: ‘In the Annex, point (1), point (2) and points (a), (b) and (c) of point (3) shall apply from 1 June 2017.’

Entry into force and application

Article 3

Open ↗

This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union . Point (1) and point (a) of point (2) of the Annex shall apply from 1 December 2019. Points (b), (c), (d) and (e) of point (2) of the Annex shall apply from 1 May 2020. By way of derogation from the third paragraph of this Article, substances and mixtures may, before 1 May 2020, be classified, labelled and packaged in accordance with Regulation (EC) No 1272/2008 as amended by this Regulation.

Supplementary provisions

ANNEXSupplementary provisions

Open ↗

ANNEX Annex VI to Regulation (EC) No 1272/2008 is amended as follows: (1) in Part 1, the heading of point 1.1.1.4 is replaced by the following: ‘ Chemical name ’; (2) in Part 3, Table 3.1 is amended as follows: (a) the title of the second column is replaced by the following: ‘Chemical name’; (b) the title of the penultimate column is replaced by the following: ‘Specific Conc. Limits, M-factors and ATEs (*) (*) ATEs for oral and dermal exposure routes are expressed in mg/kg bw, which stands for milligram per kilogram bodyweight.’; (c) the entry corresponding to index number 607-414-00-6 is deleted; (d) the entries corresponding to index numbers 006-044-00-7, 015-101-00-5, 016-096-00-2, 017-011-00-1, 025-002-00-9, 603-180-00-4, 604-014-00-3, 604-016-00-4, 604-090-00-8, 605-003-00-6, 606-047-009, 607-096-00-9, 607-103-00-5, 607-113-00-X, 607-373-00-4, 613-167-00-5, 613-205-00-0 and 614-001-00-4 are replaced by the following entries respectively: Index No Chemical name EC No CAS No Classification Labelling Specific Conc. Limits, M-factors and ATEs Notes Hazard Class and Category Code(s) Hazard statement Code(s) Pictogram, Signal Word Code(s) Hazard statement Code(s) Suppl. Hazard statement Code(s) ‘006-044-00-7 isoproturon (ISO); 3-(4-isopropylphenyl)-1,1-dimethylurea 251-835-4 34123-59-6 Carc. 2 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 H351 H373 (blood) H400 H410 GHS08 GHS09 Wng H351 H373 (blood) H410   M = 10 M = 10’   ‘015-101-00-5 phosmet (ISO); S -[(1,3-dioxo-1,3-dihydro-2 H -isoindol-2-yl)methyl] O , O -dimethyl phosphorodithioate; O , O -dimethyl- S -phthalimidomethyl phosphorodithioate 211-987-4 732-11-6 Repr. 2 Acute Tox. 4 Acute Tox. 3 STOT SE 1 Aquatic Acute 1 Aquatic Chronic 1 H361f H332 H301 H370 (nervous system) H400 H410 GHS08 GHS06 GHS09 Dgr H361f H332 H301 H370 (nervous system) H410   M = 100 M = 100’   ‘016-096-00-2 thifensulfuron-methyl (ISO); methyl 3-(4-methoxy-6-methyl-1,3,5-triazin-2-ylcarbamoylsulfamoyl)thiophene-2-carboxylate — 79277-27-3 Aquatic Acute 1 Aquatic Chronic 1 H400 H410 GHS09 Wng H410   M = 100 M = 100’   ‘017-011-00-1 sodium hypochlorite, solution … % Cl active 231-668-3 7681-52-9 Skin Corr. 1B Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 H314 H318 H400 H410 GHS05 GHS09 Dgr H314 H410 EUH031 M = 10 M = 1 EUH031: C ≥ 5 % B’ ‘025-002-00-9 potassium permanganate 231-760-3 7722-64-7 Ox. Sol. 2 Repr. 2 Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 H272 H361d H302 H400 H410 GHS03 GHS08 GHS07 GHS09 Dgr H272 H361d H302 H410’       ‘603-180-00-4 colecalciferol; cholecalciferol; vitamin D 3 200-673-2 67-97-0 Acute Tox. 2 Acute Tox. 2 Acute Tox. 2 STOT RE 1 H330 H310 H300 H372 GHS06 GHS08 Dgr H330 H310 H300 H372     inhalation: ATE = 0,05 mg/L (dusts or mists)   dermal: ATE = 50 mg/kg bw   oral: ATE = 35 mg/kg bw STOT RE 1; H372: C ≥ 3 % STOT RE 2; H373: 0,3 % ≤ C < 3 %’   ‘604-014-00-3 chlorocresol; 4-chloro-m-cresol; 4-chloro-3-methylphenol 200-431-6 59-50-7 Acute Tox. 4 Skin Corr. 1C Eye Dam. 1 STOT SE 3 Skin Sens. 1B Aquatic Acute 1 Aquatic Chronic 3 H302 H314 H318 H335 H317 H400 H412 GHS07 GHS05 GHS09 Dgr H302 H314 H335 H317 H410   M = 1’   ‘604-016-00-4 1,2-dihydroxybenzene; pyrocatechol 204-427-5 120-80-9 Carc. 1Β Muta. 2 Acute Tox. 3 Acute Tox. 3 Skin Irrit. 2 Eye Irrit. 2 H350 H341 H311 H301 H315 H319 GHS08 GHS06 Dgr H350 H341 H311 H301 H315 H319     oral: ATE = 300 mg/kg bw   dermal: ATE = 600 mg/kg bw’   ‘604-090-00-8 4- tert -butylphenol 202-679-0 98-54-4 Repr. 2 Skin Irrit. 2 Eye Dam. 1 Aquatic Chronic 1 H361f H315 H318 H410 GHS08 GHS05 GHS09 Dgr H361f H315 H318 H410   M = 1’   ‘605-003-00-6 acetaldehyde; ethanal 200-836-8 75-07-0 Flam. Liq. 1 Carc. 1B Muta. 2 STOT SE 3 Eye Irrit. 2 H224 H350 H341 H335 H319 GHS02 GHS08 GHS07 Dgr H224 H350 H341 H335 H319’       ‘606-047-00-9 2-benzyl-2-dimethylamino-4′-morpholinobutyrophenone 404-360-3 119313-12-1 Repr. 1B Aquatic Acute 1 Aquatic Chronic 1 H360D H400 H410 GHS08 GHS09 Dgr H360D H410’       ‘607-096-00-9 maleic anhydride 203-571-6 108-31-6 Acute Tox. 4 STOT RE 1 Skin Corr. 1B Eye Dam. 1 Resp. Sens. 1 Skin Sens. 1A H302 H372 (respiratory system) (inhalation) H314 H318 H334 H317 GHS07 GHS08 GHS05 Dgr H302 H372 (respiratory system) (inhalation) H314 H334 H317 EUH071 Skin Sens. 1A; H317: C ≥ 0,001 %’   ‘607-103-00-5 succinic anhydride 203-570-0 108-30-5 Acute Tox. 4 Skin Corr. 1 Eye Dam. 1 Resp. Sens. 1 Skin Sens. 1 H302 H314 H318 H334 H317 GHS07 GHS05 GHS08 Dgr H302 H314 H334 H317 EUH071’     ‘607-113-00-X isobutyl methacrylate 202-613-0 97-86-9 Flam. Liq. 3 STOT SE 3 Skin Irrit. 2 Skin Sens. 1B H226 H335 H315 H317 GHS02 GHS07 Wng H226 H335 H315 H317     D’ ‘607-373-00-4 quizalofop-P-tefuryl (ISO); (+/–) tetrahydrofurfuryl (R)-2-[4-(6-chloroquinoxalin-2-yloxy)phenyloxy]propionate 414-200-4 200509-41-7 Carc. 2 Repr. 2 Acute Tox. 4 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 H351 H361fd H302 H373 H400 H410 GHS08 GHS07 GHS09 Wng H351 H361fd H302 H373 H410   M = 1 M = 1’   ‘613-167-00-5 reaction mass of 5-chloro-2-methyl-2 H -isothiazol-3-one and 2-methyl-2 H -isothiazol-3-one (3:1) — 55965-84-9 Acute Tox. 2 Acute Tox. 2 Acute Tox. 3 Skin Corr. 1C Eye Dam. 1 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 1 H330 H310 H301 H314 H318 H317 H400 H410 GHS06 GHS05 GHS09 Dgr H330 H310 H301 H314 H317 H410 EUH071 Skin Corr. 1C; H314: C ≥ 0,6 % Skin Irrit. 2; H315: 0,06 % ≤ C < 0,6 % Eye Dam. 1; H318: C ≥ 0,6 % Eye Irrit. 2; H319: 0,06 % ≤ C < 0,6 % Skin Sens. 1A; H317: C ≥ 0,0015 % M = 100 M = 100 B’ ‘613-205-00-0 propiconazole (ISO); (2 RS ,4 RS ;2 RS ,4 SR )-1-{[2-(2,4-dichlorophenyl)-4-propyl-1,3-dioxolan-2-yl]methyl}-1 H -1,2,4-triazole 262-104-4 60207-90-1 Repr. 1B Acute Tox. 4 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H360D H302 H317 H400 H410 GHS08 GHS07 GHS09 Dgr H360D H302 H317 H410   M = 1 M = 1’   ‘614-001-00-4 nicotine (ISO); 3-[(2S)-1-methylpyrrolidin-2-yl]pyridine 200-193-3 54-11-5 Acute Tox. 2 Acute Tox. 2 Acute Tox. 2 Aquatic Chronic 2 H330 H310 H300 H411 GHS06 GHS09 Dgr H330 H310 H300 H411     inhalation: ATE = 0,19 mg/L (dusts or mists)   dermal: ATE = 70 mg/kg bw   oral: ATE = 5 mg/kg bw’   (e) the following entries are inserted in the appropriate places, following the order of the entries set out in Table 3.1: Index No Chemical name EC No CAS No Classification Labelling Specific Conc. Limits, M-factors and ATEs Notes Hazard Class and Category Code(s) Hazard statement Code(s) Pictogram, Signal Word Code(s) Hazard statement Code(s) Suppl. Hazard statement Code(s) ‘604-094-00-X isoeugenol; [1] ( E )-2-methoxy-4-(prop-1-enyl)phenol; [2] ( Z )-2-methoxy-4-(prop-1-enyl)phenol [3] 202-590-7 [1] 227-678-2 [2] 227-633-7 [3] 97-54-1 [1] 5932-68-3 [2] 5912-86-7 [3] Skin Sens. 1A H317 GHS07 Wng H317   Skin Sens. 1A; H317: C ≥ 0,01 %’   ‘607-724-00-1 2,3,5,6-tetrafluoro-4-(methoxymethyl)benzyl (1 R ,3 R )-2,2-dimethyl-3-[(1 Z )-prop-1-en-1-yl]cyclopropanecarboxylate; epsilon-metofluthrin — 240494-71-7 Acute Tox. 4 Acute Tox. 3 STOT SE 1 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 H332 H301 H370 (nervous system) H373 H400 H410 GHS06 GHS08 GHS09 Dgr H332 H301 H370 (nervous system) H373 H410   M = 100 M = 100’   ‘607-725-00-7 isopropyl (2 E ,4 E ,7 S )-11-methoxy-3,7,11-trimethyldodeca-2,4-dienoate; S -methoprene — 65733-16-6 Aquatic Acute 1 Aquatic Chronic 1 H400 H410 GHS09 Wng H410   M = 1 M = 1’   ‘607-726-00-2 pinoxaden (ISO); 8-(2,6-diethyl-4-methylphenyl)-7-oxo-1,2,4,5-tetrahydro-7 H -pyrazolo[1,2-d][1,4,5]oxadiazepin-9-yl 2,2-dimethylpropanoate — 243973-20-8 Repr. 2 Acute Tox. 4 Acute Tox. 4 Eye Irrit. 2 STOT SE 3 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 3 H361d H332 H302 H319 H335 H317 H400 H412 GHS08 GHS07 GHS09 Wng H361d H332 H302 H319 H335 H317 H410     inhalation: ATE = 4,63 mg/L (dusts or mists)   oral: ATE = 500 mg/kg bw M = 1’   ‘607-727-00-8 tetramethrin (ISO); (1,3-dioxo-1,3,4,5,6,7-hexahydro-2 H -isoindol-2-yl)methyl 2,2-dimethyl-3-(2-methylprop-1-en-1-yl)cyclopropanecarboxylate 231-711-6 7696-12-0 Carc. 2 Acute Tox. 4 STOT SE 2 Aquatic Acute 1 Aquatic Chronic 1 H351 H302 H371 (nervous system) (inhalation) H400 H410 GHS08 GHS07 GHS09 Wng H351 H302 H371 (nervous system) (inhalation) H410   M = 100 M = 100’   ‘607-728-00-3 (1,3,4,5,6,7-hexahydro-1,3-dioxo- 2H -isoindol-2-yl)methyl (1 R - trans )-2,2-dimethyl-3-(2-methylprop-1-enyl)cyclopropanecarboxylate 214-619-0 1166-46-7 Carc. 2 Acute Tox. 4 STOT SE 2 Aquatic Acute 1 Aquatic Chronic 1 H351 H302 H371 (nervous system) (inhalation) H400 H410 GHS08 GHS07 GHS09 Wng H351 H302 H371 (nervous system) (inhalation) H410   M = 100 M = 100’   ‘607-729-00-9 mesosulfuron-methyl (ISO); methyl 2-[(4,6-dimethoxypyrimidin-2-ylcarbamoyl)sulfamoyl]-α-(methanesulfonamido)- p -toluate; — 208465-21-8 Aquatic Acute 1 Aquatic Chronic 1 H400 H410 GHS09 Wng H410   M = 100 M = 100’   ‘607-730-00-4 spirodiclofen (ISO); 3-(2,4-dichlorophenyl)-2-oxo-1-oxaspiro[4.5]dec-3-en-4-yl 2,2-dimethylbutyrate — 148477-71-8 Carc. 1B Repr. 2 STOT RE 2 Skin Sens. 1B Aquatic Chronic 1 H350 H361f H373 H317 H410 GHS08 GHS07 GHS09 Dgr H350 H361f H373 H317 H410   M = 10’   ‘607-731-00-X sodium methyl [(4-aminophenyl)sulphonyl]carbamate; sodium methyl ( EZ )-sulfanilylcarbonimidate; asulam-sodium 218-953-8 2302-17-2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H317 H400 H410 GHS07 GHS09 Wng H317 H410   M = 1 M = 1’   ‘607-732-00-5 salicylic acid 200-712-3 69-72-7 Repr. 2 Acute Tox. 4 Eye Dam. 1 H361d H302 H318 GHS08 GHS07 GHS05 Dgr H361d H302 H318’       ‘608-068-00-9 flutianil (ISO); (2 Z )-{[2-fluoro-5-(trifluoromethyl)phenyl]thio}[3-(2-methoxyphenyl)-1,3-thiazolidin-2-ylidene]acetonitrile — 958647-10-4 Aquatic Chronic 1 H410 GHS09 Wng H410   M = 100’   ‘612-293-00-8 reaction mass of 1-[2-(2-aminobutoxy)ethoxy]but-2-ylamine and 1-({[2-(2-aminobutoxy)ethoxy]methyl}propoxy)but-2-ylamine 447-920-2 - Repr. 2 Acute Tox. 4 Skin Corr. 1B Eye Dam. 1 H361f H302 H314 H318 GHS08 GHS07 GHS05 Dgr H361f H302 H314 EUH071’     ‘613-326-00-9 2-methylisothiazol-3(2 H )-one 220-239-6 2682-20-4 Acute Tox. 2 Acute Tox. 3 Acute Tox. 3 Skin Corr. 1B Eye Dam. 1 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 1 H330 H311 H301 H314 H318 H317 H400 H410 GHS05 GHS06 GHS09 Dgr H330 H311 H301 H314 H317 H410 EUH071 Skin Sens. 1A; H317: C ≥ 0,0015 % M = 10 M = 1’   ‘613-327-00-4 pyroxsulam (ISO); N -(5,7-dimethoxy[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)-2-methoxy-4-(trifluoromethyl)pyridine-3-sulfonamide — 422556-08-9 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H317 H400 H410 GHS07 GHS09 Wng H317 H410   M = 100 M = 100’   ‘613-328-00-X 1-vinylimidazole 214-012-0 1072-63-5 Repr. 1B H360D GHS08 Dgr H360D   Repr. 1B; H360D: C ≥ 0,03 %’   ‘616-224-00-2 amisulbrom (ISO); 3-(3-bromo-6-fluoro-2-methylindol-1-ylsulfonyl)- N,N -dimethyl-1 H -1,2,4-triazole-1-sulfonamide — 348635-87-0 Carc. 2 Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 H351 H319 H400 H410 GHS08 GHS07 GHS09 Wng H351 H319 H410   M = 10 M = 10’

Other acts of the same type
Commission Implementing Regulation (EU) 2022/2312 of 25 November 2022 on eight-yearly variables in the labour force domain on ‘young people on the labour market’, ‘educational attainment – details, including education interrupted or abandoned’ and ‘reconciliation of work and family life’ pursuant to Regulation (EU) 2019/1700 of the European Parliament and of the Council (Text with EEA relevance)Commission Implementing Regulation (EU) 2022/2313 of 25 November 2022 entering a name in the register of traditional specialities guaranteed (Pizza Napoletana (TSG))Commission Implementing Regulation (EU) 2022/2314 of 25 November 2022 renewing the approval of the active substance Pythium oligandrum strain M1 in accordance with Regulation (EC) No 1107/2009 of the European Parliament and of the Council concerning the placing of plant protection products on the market, and amending the Annex to Commission Implementing Regulation (EU) No 540/2011 (Text with EEA relevance)Commission Implementing Regulation (EU) 2022/2315 of 25 November 2022 renewing the approval of the low-risk active substance heptamaloxyloglucan in accordance with Regulation (EC) No 1107/2009 of the European Parliament and of the Council concerning the placing of plant protection products on the market, and amending the Annex to Commission Implementing Regulation (EU) No 540/2011 (Text with EEA relevance)Commission Implementing Regulation (EU) 2022/2316 of 25 November 2022 amending Annexes V and XIV to Implementing Regulation (EU) 2021/404 as regards the entries for Canada, the United Kingdom and the United States in the lists of third countries authorised for the entry into the Union of consignments of poultry, germinal products of poultry and fresh meat of poultry and game birds (Text with EEA relevance)Commission Delegated Regulation (EU) 2023/196 of 25 November 2022 amending Regulation (EC) No 273/2004 of the European Parliament and of the Council and Council Regulation (EC) No 111/2005 as regards the inclusion of certain drug precursors in the list of scheduled substances (Text with EEA relevance)Commission Delegated Regulation (EU) 2023/450 of 25 November 2022 supplementing Regulation (EU) 2021/23 of the European Parliament and of the Council with regard to regulatory technical standards specifying the order in which CCPs are to pay the recompense referred to in Article 20(1) of Regulation (EU) 2021/23, the maximum number of years during which those CCPs are to use a share of their annual profits for such payments to possessors of instruments recognising a claim on their future profits and the maximum share of those profits that is to be used for those payments (Text with EEA relevance)Commission Delegated Regulation (EU) 2023/451 of 25 November 2022 specifying the factors to be taken into consideration by the competent authority and the supervisory college when assessing the recovery plan of central counterparties (Text with EEA relevance)Commission Delegated Regulation (EU) 2023/840 of 25 November 2022 supplementing Regulation (EU) 2021/23 of the European Parliament and of the Council with regard to regulatory technical standards specifying the methodology for calculation and maintenance of the additional amount of pre-funded dedicated own resources to be used in accordance with Article 9(14) of that Regulation (Text with EEA relevance)Commission Implementing Regulation (EU) 2022/2303 of 24 November 2022 amending Implementing Regulation (EU) 2019/1780 establishing standard forms for the publication of notices in the field of public procurement (Text with EEA relevance)Commission Implementing Regulation (EU) 2022/2304 of 24 November 2022 designating the European Union reference laboratory for Rift Valley fever (Text with EEA relevance)Commission Implementing Regulation (EU) 2022/2305 of 24 November 2022 renewing the approval of the low-risk active substance Fish oil in accordance with Regulation (EC) No 1107/2009 of the European Parliament and of the Council concerning the placing of plant protection products on the market, and amending the Annex to Commission Implementing Regulation (EU) No 540/2011 (Text with EEA relevance)

Source: EUR-Lex (Publications Office of the EU), © European Union, reuse permitted under Commission Decision 2011/833/EU.

Contents

What to look at next